We’re proud to share that our CEO & Co- Founder, Aaron Edwards, was recently interviewed on The Sheekey Science Show , a leading science communication platform hosted by Eleanor Sheekey. In this in-depth conversation, Aaron shares KiraGen’s founding story and how we’re building a new generation of CAR-T therapies—multiplex gene-edited and AI-guided—to overcome the immunosuppressive barriers of solid tumors, starting with glioblastoma (GBM). Key topics include: Why the tumor microenvironment remains a major barrier for cell therapy How KiraGen uses combinatorial gene editing to engineer durable CAR-T responses The role of AI in designing better cell therapies Why we believe GBM is the ideal first application Insights for the next generation of biotech entrepreneurs 🎧 Watch the full episode here : https://youtu.be/OMOCa8DmJxQ We’re grateful to Eleanor for the thoughtful conversation and for helping bring scientific innovation to broader audiences.

We are excited to announce a significant milestone for KiraGen Bio and our mission towards inclusive innovation: Aaron Edwards, our Co-Founder and CEO, has been selected as a 2024 Termeer Fellow . This achievement is not only a testament to Aaron's visionary leadership in developing advanced CAR-T cell therapies for solid tumors but also reflects our shared commitment to fostering diversity and inclusivity at the leadership level in biotech. The Termeer Foundation champions values-driven leadership, emphasizing the importance of broadening representation within the biopharmaceutical industry—particularly for women, people with disabilities, LGBTQIA+ individuals, and Black, Brown, and Indigenous People of Color. Aaron's selection aligns with KiraGen's core values of innovation, inclusivity, and transformational change in healthcare. Through this fellowship, Aaron will gain access to an invaluable network of mentoring, professional development, and peer-to-peer sharing opportunities, further empowering KiraGen to break down silos and lead the way in developing life-changing cancer treatments. Discover more about the Termeer Fellowship and its commitment to inclusivity here .

We’re thrilled to share that KiraGen Bio has been selected to join the inaugural cohort of the new AI BioHub , a bold initiative from LabCentral and C10 Labs at the heart of Kendall Square. Backed by a $1.9M grant from MassTech , this program is designed to close the gap between AI’s promise and experimental reality —exactly where KiraGen thrives. At KiraGen, we’re engineering multiplex-edited CAR-T therapies to overcome the suppressive tumor microenvironment in solid tumors. The KiraLOGIC platform integrates wet-lab data and AI to rationally design these edits—making this AI-first accelerator a perfect fit for our mission. As part of the AI BioHub, we’ll gain: Access to cutting-edge wet lab + compute infrastructure A curated community of AI-native biotech entrepreneurs Hands-on support from leaders like Anna Marie Wagner and Shahid Azim Entrepreneurial programming and investor access to scale our impact This isn’t just an accelerator. It’s a launchpad for the next generation of AI-biology companies—and we’re honored to be part of it. Stay tuned as we put AI in the loop of drug discovery. 🔗 Learn more about the AI BioHub: https://www.labcentral.org/startup-support/ai-biohub 🔗 Read the official press release: https://www.labcentral.org/events-and-media/press-releases/labcentral-and-c10-labs-unveil-new-ai-biohub-in-kendall-square #TechBio #AIBio #CellTherapy #AIinBiotech #LabCentral #C10Labs #KiraGenBio #GBM #DrugDiscovery

We’re excited to announce that KiraGen Bio has been selected as one of ten companies in the Recode Edge ’25 cohort —a highly competitive pre-seed program designed to back early-stage teams using artificial intelligence to solve major healthcare challenges. Out of more than 200 applicants, Recode Ventures selected just ten companies that exemplify bold thinking, novel technology, and the potential to reshape the future of health. As part of the program, we’ll receive hands-on support from the Recode team and partners including Eli Lilly and Company , Amazon Web Services (AWS) , OpenAI , DLA Piper , and JPMorgan Chase . We’ll also attend an exclusive bootcamp in Chicago alongside other trailblazing startups in healthcare AI. Being part of this cohort puts us in the running for up to $2 million in follow-on investment , which would be catalytic as we continue building out KiraLOGIC —our AI-driven platform that identifies optimal multiplex gene editing combinations to overcome tumor microenvironment (TME) suppression in solid tumors. At KiraGen, we’re focused on engineering next-generation cell therapies starting with glioblastoma (GBM), one of the most challenging and underserved cancers. Our team—drawn from leaders at Beam Therapeutics, Bluebird Bio, and Harvard—knows what it takes to bring cutting-edge science into the clinic. The Recode Edge program is an incredible opportunity to accelerate that mission. We’re honored to be part of this inspiring group and grateful to Recode and their partners for believing in our vision. Let’s build.

We are excited to announce that KiraGen Bio has been selected as a Boston Regional Finalist in the Harvard Business School (HBS) New Venture Competition – Alumni Track ! This milestone puts us one step closer to the Global Finals , where the winning team will receive a $75,000 grand prize . A Testament to Innovation and Impact The HBS New Venture Competition is a prestigious platform that brings together top ventures from around the world, recognizing startups that demonstrate transformative potential. Making it to the Boston Regional Finals is a significant validation of our mission to engineer multiplex-edited cell therapies that conquer the tumor microenvironment (TME) and transform the treatment of solid tumors . KiraGen Bio is at the forefront of next-generation cell therapy innovation, leveraging AI-driven gene editing strategies to enhance CAR-T cell persistence and efficacy in solid tumors. Our lead program in glioblastoma (GBM) builds upon the foundation set by leading academic institutions and represents a meaningful step toward improving treatment outcomes for patients with some of the most challenging cancers. What’s Next? As we prepare to compete in the Boston Regional Finals , we are eager to share our vision with a distinguished panel of judges, investors, and industry leaders. The Regional winners will advance to the Global Finals , where they will compete for the top prize and global recognition among HBS alumni-founded startups. This achievement is a reflection of the dedication and hard work of our team, as well as the incredible support from our advisors, collaborators, and community. We look forward to representing KiraGen Bio in this competition and continuing our mission to push the boundaries of solid tumor cell therapy innovation . Stay tuned for updates as we move forward in the competition!

Boston, USA, April 2, 2024 - KiraGen Bio, a pioneering biotech company in the field of innovative cellular therapies for solid tumors, is pleased to announce today a strategic partnership with Flash BioSolutions, a leading CDMO providing state-of-the-art lentiviral particles. This collaboration aims to fully harness the potential of CAR-T (Chimeric Antigen Receptor T-cell) therapies in cancer treatment. Through this alliance, KiraGen Bio will leverage the advanced expertise of Flash BioSolutions and its flagship technology, LentiCare®. This cutting-edge lentiviral platform will be seamlessly integrated into the development of KiraGen Bio's groundbreaking CAR-T therapies, playing a crucial role in the Proof of Concept stage and beyond. The revolutionary aspect of this partnership lies in the synergistic combination of KiraGen Bio's proprietary AI-driven platform, KiraLOGIC, and Flash BioSolutions' state-of-the-art LentiCare® technology. KiraLOGIC employs advanced machine learning algorithms to rationally design CAR-T cells equipped with a combination of highly multiplexed gene edits, rendering them resistant to the immunosuppressive tumor microenvironment. By integrating these AI-powered gene editing capabilities with the high-quality lentiviral vectors provided by Flash BioSolutions, KiraGen Bio is poised to unlock the full potential of CAR-T therapies for solid tumors, addressing a critical unmet need in cancer treatment. "Our KiraLOGIC platform leverages AI to rationally design CAR-T cells resistant to immunosuppression, unlocking the potential of cell therapies for solid tumors. Partnering with Flash BioSolutions, a leader in lentiviral vector manufacturing, is pivotal in advancing our multiplex gene-edited CAR-T therapies. Their LentiCare® technology ensures high-quality lentiviral vectors, essential for generating robust preclinical data and propelling our therapies towards clinical development. Together, we are poised to accelerate scientific progress and deliver transformative treatments to patients in need," stated Ryan Murray, PhD, CSO & Co-Founder of KiraGen Bio. "At KiraGen, our unwavering commitment is to bring our revolutionary TME-Guard technology to patients as quickly and broadly as possible. Collaborating with Flash BioSolutions is a significant milestone in realizing this vision. Their deep expertise in lentiviral manufacturing will be instrumental as we rapidly advance our innovative cell therapies through preclinical development and into the clinic. This strategic partnership is key to accelerating our lead programs, forging powerful industry and academic alliances, and building a robust and sustainable pipeline. By joining forces with Flash BioSolutions, we are creating a powerful model that can drive transformative impact for patients while generating value for our investors, as we work to establish KiraGen as a pioneer in solid tumor cell therapy," added Aaron Edwards, CEO & Co-Founder of KiraGen Bio. "Flash BioSolutions is thrilled to collaborate with KiraGen Bio in reshaping the paradigm of CAR-T therapies for solid tumors," stated Jérôme Bédier, CEO of Flash BioSolutions. "Through the potent fusion of our expertise and state-of-the-art technologies, we are steadfast in our commitment to propelling scientific innovation and introducing revolutionary treatment options for patients confronting this formidable disease." This partnership between Flash BioSolutions and KiraGen Bio embodies the commitment of both companies to push the boundaries of research to improve the lives of cancer patients. Together, they aspire to open new perspectives in the treatment of solid tumors and bring renewed hope to those battling this disease. About KiraGen Bio: KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies for solid tumors. By leveraging its proprietary KiraLOGIC platform, KiraGen Bio engineers CAR-T cells with up to 8 tumor microenvironment (TME) resistance gene edits, directly targeting the root cause of immunosuppression. Co-founded by experts from bluebird bio, Beam Therapeutics, and Harvard Business School, KiraGen Bio is committed to pushing the boundaries of science to bring the curative potential of cell therapies to the 90% of cancer patients currently underserved by CAR-T. About Flash BioSolutions: Flash BioSolutions is a CDMO specialized in the industrial production of DNA or RNA vectors for clients in gene and cell therapies, and vaccines. Flash BioSolutions has a robust platform and manufacturing process, proven over 20 years, enabling the delivery of high-purity and high-concentration vectors for research, preclinical, clinical, and commercial phases. Head of communication Soraya Sandokchi +33 582 955 546 soraya.sandokchi@flashbiosolutions.com

We are thrilled to announce that our co-founder and CEO, Aaron Edwards, was recently featured as a special guest on the esteemed "Beyond the Square" podcast, hosted by William Wang. In this illuminating episode, Aaron delves into the pivotal role of AI in gene therapy, particularly focusing on the groundbreaking strides KiraGen Bio is making with CAR T cell technology in the fight against solid tumors. Aaron shares his insights on the potential of gene therapy, the challenges and solutions in delivery mechanisms, and the inspiring journey that led to the inception of KiraGen Bio. His forward-thinking vision for the company and his commitment to transparency and open communication are evident throughout the discussion. Furthermore, Aaron casts light on the current biotech industry trends and the incredible promise of extending health spans through advancements in longevity science. This episode is a must-listen for anyone interested in the future of biotechnology and the innovative use of AI to surmount healthcare challenges. Listen to the full conversation on Spotify here: Beyond the Square - Aaron Edwards: The Science of Survival, a Quest to Conquer Solid Tumors with KiraGen Bio

We are thrilled to announce KiraGen Bio's participation in the prestigious Harvard New Venture Competition, a testament to our dedication to pioneering advancements in CAR-T cell therapies for solid tumors. Amidst a competitive field of 78 innovative teams, KiraGen Bio showcased our groundbreaking approach to conquering the challenges of the tumor microenvironment (TME) and enhancing gene editing strategies for CAR-T cells. The Business Track of the New Venture Competition served as an invaluable platform for integrating entrepreneurship principles into our mission. It enabled us to not only present our AI-driven platform but also engage with the complex process of transforming our research into viable, life-saving treatments. Throughout the competition, the feedback we received was immensely beneficial, offering insights that will fuel our progress. Whether advancing to the next round or not, the experience has been enriching, reinforcing our commitment to excellence and innovation in biotechnology. As we continue our journey at KiraGen Bio, we remain focused on merging advanced AI with deep biological understanding to revolutionize CAR-T cell therapies. Our participation in Harvard's New Venture Competition underscores our passion and dedication to making a significant impact in the fight against solid tumors. Stay tuned for more updates on our journey and how we're transforming the landscape of cancer treatment, one innovation at a time. #KiraGenBio #Innovation #HBSNVC #Biotech #CARTTherapies

KiraGen has been selected as a finalist in the 13th @UMassM2D2 2024 #200KChallenge! Join us IN-PERSON in Lowell at the Finalist Pitch-Off on March 27. Details and FREE registration: https://www.eventbrite.com/e/m2d2-2024-200k-challenge-pitch-off-awards-announcement-tickets-800212014677?aff=finalistpackage

KiraGen Bio has been selected as finalists for the 2024 Cohort of Nucleate's Activator Program, specifically within the Boston region, amongst 18 distinguished teams. This selection highlights KiraGen's role in pioneering CAR-T cell therapies for solid tumors, leveraging combinatorial gene editing and AI to push the boundaries of cancer treatment. The inclusion in Boston's cohort of Nucleate’s Activator Program represents a key milestone for KiraGen, providing access to critical support and networking opportunities in one of the world’s leading biotech hubs. As the program unfolds, we invite our community to stay tuned for updates on our progress and the innovative strides we're making in the program!

Navigating the vibrant and diverse ecosystem of the Harvard Business School Shark Tank competition, KiraGen Bio is proud to have secured a place in the semi-finals, distinguishing ourselves in a field often dominated by sectors such as consumer goods, tech, and real estate. Our advancement is noteworthy, reflecting not just the potential of our AI-driven CAR-T cell therapies but also the significance of biotechnology in an entrepreneurial landscape rich with varied industries. This achievement speaks volumes about the resonance of our vision to innovate cancer treatment and the dedication of our team to make a meaningful impact in a complex and crucial field of healthcare. It's a commendable milestone for KiraGen Bio, emphasizing the growing importance and recognition of biotech in the broader tapestry of business innovation.

We're excited to share a pivotal update from KiraGen Bio: our move to the Harvard Pagliuca Harvard Life Lab. This transition is a significant stride in our quest to revolutionize CAR-T cell therapies for solid tumors, positioning us within a hub of biotech innovation. The Life Lab's state-of-the-art facilities and vibrant community enhance our capability to tackle the tumor microenvironment and refine gene editing for more effective cancer treatments. This move amplifies our efforts, connecting us with fellow innovators and expanding our reach in the biotech landscape. It's a leap forward in our mission, promising to accelerate our impact on cancer therapy. Join us on this exhilarating journey as we continue to push the boundaries of medical science.